OnKure Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

OKUR$3.19+11.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except par value and share data)

	December 31,	December 31,
	2025	2024
ASSETS
Current assets:
Cash and cash equivalents	$59,050	$110,761
Prepaid expenses and other current assets	1,789	2,242
Total current assets	60,839	113,003
Property and equipment, net	618	1,025
Operating lease right-of-use asset	387	770
Other assets	273	109
Total assets	$62,117	$114,907
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$1,433	$2,968
Accrued expenses and other current liabilities	3,939	7,026
Operating lease liabilities, current portion	549	536
Total current liabilities	5,921	10,530
Long-term operating lease liabilities	—	549
Other long-term liabilities	12	—
Total liabilities	5,933	11,079
Commitments and contingencies
Stockholders’ equity:
Common stock, Class A, $0.0001 par value; 200,000,000 shares authorized; 13,673,565 and 12,660,590 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	1	1
Common stock, Class B, $0.0001 par value; 10,000,000 shares authorized; no shares and 686,527 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	—	—
Additional paid-in capital	270,424	258,551
Accumulated deficit	(214,241)	(154,724)
Total stockholders’ equity	56,184	103,828
Total liabilities and stockholders’ equity	$62,117	$114,907

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.